The therapeutic potential of nanoscale sphingolipid technologies

Handbook of Experimental Pharmacology

Volumn 215, Issue , 2013, Pages 197-210

  Hankins, Jody L ^a   Doshi, Ushma A ^a   Haakenson, Jeremy K ^a   Young, Megan M ^a   Barth, Brian M ^a   Kester, Mark ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Ceramide; Liposome; Nanotechnology; Sphingolipid; Therapy

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ACTIVE PHARMACEUTICAL INGREDIENT; C6 CERAMIDE; C8 CERAMIDE; CALCIUM PHOSPHOSILICATE NANOPARTICLE; CERAMIDE; CERAMIDE 3; CERAMIDE DERIVATIVE; CHEMICAL COMPOUND; CHOLESTEROL; DOXORUBICIN; FINGOLIMOD; FLUOROURACIL; GANGLIOSIDE GM1; LINEAR DENDRITIC NANOPARTICLE; LIPOSOME; MACROGOL; MACROGOL 2000; NANOLIPOSOME; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID; POLYETHYLENE 750; POLYETHYLENEOXIDE MODIFIED POLYEPSILON CAPROLACTONE NANOPARTICLE; POLYMER; SPHINGOLIPID; SPHINGOMYELIN; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER THERAPY; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; DRUG EFFECT; IMMUNITY; NEOPLASM; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; IMMUNITY; LIPOSOMES; NANOTECHNOLOGY; NEOPLASMS; SPHINGOLIPIDS;

MLCS; MLOWN;

EID: 84880445857     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1368-4_11     Document Type: Article

References (70)

1. Adair JH, Parette MP, Altinoglu EI, Kester M (2010) Nanoparticulate alternatives for drug delivery. ACS Nano 4(9):4967-4970
2. Adrian JE, Wolf A, Steinbach A, Rossler J, Suss R (2011) Targeted delivery to neuroblastoma ofnovel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterolbased post-insertion method. Pharm Res 28(9):2261-2272
3. Alewijnse AE, Peters SL (2008) Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 585(2-3):292-302
4. Allen TM, Chonn A (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223(1):42-46
5. Allen TM, Hansen C, Rutledge J (1989) Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981(1):27-35
6. Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13(1):238-252
7. Barbet J, Machy P, Leserman LD (1981) Monoclonal antibody covalently coupled to liposomes: specific targeting to cells. J Supramol Struct Cell Biochem 16(3):243-258
8. Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, Cabot MC, Kester M, Kuhn TB (2010a) Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biol Ther 10(11):1126-1136
9. Barth BM, Sharma R, Altinoglu EI, Morgan TT, Shanmugavelandy SS, Kaiser JM, cGovern C, Matters GL, Smith JP, Kester M, Adair JH (2010b) Bioconjugation of calcium phosphosilicatecomposite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo.ACS Nano 4(3):1279-1287
10. Barth BM, Cabot MC, Kester M (2011) Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med Chem 11(9):911-919
11. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M (1995) Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci84(4):493-498
12. Bischoff A, Czyborra P, Meyer Zu Heringdorf D, Jakobs KH, Michel MC (2000) Sphingosine-1- phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitivemanner. Br J Pharmacol 130(8):1878-1883
13. Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V (2008) Organelle- targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicityin vitro and in vivo. Nano Lett 8(8):2559-2563
14. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277(24):21453-21457
15. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P(2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9(11):883-897
16. Charles R, Sandirasegarane L, Yun J, Bourbon N, Wilson R, Rothstein RP, Levison SW, Kester M (2000) Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res 87(4):282-288
17. Chiba N, Masuda A, Yoshikai Y, Matsuguchi T (2007) Ceramide inhibits LPS-induced production of IL-5, IL-10, and IL-13 from mast cells. J Cell Physiol 213(1):126-136
18. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, Kim K, Kwon IC, Kim DD (2011) Selfassembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic(R) for tumor-targeted delivery of docetaxel. Biomaterials 32(29):7181-7190
19. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH, Shim JS, Kim K, Kwon IC, Kim DD (2012) Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 33(4):1190-1200
20. Desai A, Vyas T, Amiji M (2008) Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 97(7):2745-2756
21. Devalapally H, Duan Z, Seiden MV, Amiji MM (2007) Paclitaxel and ceramide co- administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 121(8):1830-1838
22. Devalapally H, Duan Z, Seiden MV, Amiji MM (2008) Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 14(10):3193-3203
23. Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK (2011) A phaseclinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 17(8):2484-2492
24. Dobrovolskaia MA, McNeil SE (2007) Immunological properties of engineered nanomaterials. Nat Nanotechnol 2(8):469-478
25. Edmonds Y, Milstien S, Spiegel S (2011) Development of small-molecule inhibitors of sphingosine- 1-phosphate signaling. Pharmacol Ther 132(3):352-360
26. Gregoriadis G, Ryman BE (1972) Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases. Eur J Biochem 24(3):485-491
27. Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M (2011) Exogenous ceramide-1- phosphatereduces lipopolysaccharide (LPS)-mediated cytokine expression. J Biol Chem 286(52):44357-44366
28. Haxby JA, Gotze O, Muller-Eberhard HJ, Kinsky SC (1969) Release of trapped marker from liposomes by the action of purified complement components. Proc Natl Acad Sci U S A 64(1): 290-295
29. Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R, Stella PJ, Alberts SR, Pittelkow M, Sloan J, Pagano R (2003) A phase II study of topical ceramides forcutaneous breast cancer. Breast Cancer Res Treat 80(1):99-104
30. Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HRS, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M (2011) Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide forpancreatic cancer. Cancer Biol Ther 12(7):574-585
31. Jozefowski S, Czerkies M, Lukasik A, Bielawska A, Bielawski J, Kwiatkowska K, Sobota A (2010) Ceramide and ceramide 1-phosphate are negative regulators of TNF-α production induced by lipopolysaccharide. J Immunol 185(11):6960-6973
32. Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison SD Jr, Susick RL Jr (1995) Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol 25(2):201-217
33. Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH (2008) Calcium phosphate anocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett 8(12):4116-4121
34. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268(1):235-237
35. Koshkaryev A, Piroyan A, Torchilin VP (2012) Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol Ther 13(1):50-60
36. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75(1):1-18
37. Lachmann PJ, Munn EA, Weissmanng (1970) Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology 19(6):983-986
38. Lamour NF, Wijesinghe DS, Mietla JA, Ward KE, Stahelin RV, Chalfant CE (2011) Ceramide kinase regulates the production of tumor necrosis factor alpha (TNFalpha) via inhibition of TNFalpha-converting enzyme. J Biol Chem 286(50):42808-42817
39. Larrick JW, Cresswell P (1979) Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 11(4):579-586
40. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, ZhangR, Liao J, Sayers TJ, Kester M, Loughran TP Jr (2010) Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 116 (20):4192-4201
41. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566):346-349
42. Maruyama K, Kennel SJ, Huang L (1990) Lipid composition is important for highly fficient target binding and retention of immunoliposomes. Proc Natl Acad Sci U S A 87(15): 5744-5748
43. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355-360
44. Matsumura Y, Maeda H (1986) A New concept for macromolecular therapeutics in ancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Part 1):6387-6392
45. Morgan TT, Muddana HS, Altinoǧlu EI, Rouse SM, Tabaković A, Tabouillot T, Russin TJ, Shanmugavelandy SS, Butler PJ, Eklund PC, Yun JK, Kester M, Adair JH (2008) Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett 8(12):4108-4115
46. O'Neill SM, Olympia DK, Fox TE, Brown JT, Stover TC, Houck KL, Wilson R, Waybill P, Kozak M, Levison SW, Weber N, Karavodin LM, Kester M (2008) C(6)-ceramide-coated atheterspromote re-endothelialization of stretch-injured arteries. Vasc Dis Prev 5(3):200- 210
47. Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M (1999) GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 81(2):268-274
48. Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M (2003) Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.Clin Cancer Res 9(12):4595-4605
49. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M (2006) Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 66(20):10073-10082
50. Peters SL, Alewijnse AE (2007) Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 7(2):186-192
51. Product Information Booklet. http://doxil.com/assets/DOXIL-PI-Booklet.pdf Accessed 3 Mar 2012
52. Rahman AM, Yusuf SW, Ewer MS (2007) Anthracycline-induced cardiotoxicity and the cardiacsparing effect of liposomal formulation. Int J Nanomedicine 2(4):567-583
53. Rozenova KA, Deevska GM, Karakashian AA, Nikolova-Karakashian MN (2010) Studies on the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor alpha (TNFalpha)-converting enzyme activity and TNFalpha secretion in macrophages. J Biol Chem 285(27):21103-21113
54. Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M, Vrana KE (2009) Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev 18(1):55-65
55. Shabbits JA, Mayer LD (2003a) High ceramide content liposomes with in vivo antitumor activity. Anticancer Res 23(5A):3663-3669
56. Shabbits JA, Mayer LD (2003b) Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 1612(1):98-106
57. Siskind LJ, Colombini M (2000) The lipids C2- and C16-ceramide form large stable channels. Implications for apoptosis. J Biol Chem 275(49):38640-38644
58. Stover T, Kester M (2003) Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 307(2):468-475
59. Stover TC, Sharma A, Robertson GP, Kester M (2005) Systemic delivery of liposomal short- chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 11(9):3465-3474
60. Stover TC, Kim YS, Lowe TL, Kester M (2008) Thermoresponsive and biodegradable lineardendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29(3):359-369
61. Sun Y, Fox T, Adhikary G, Kester M, Pearlman E (2008) Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol 83(6):1512-1521
62. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, Jiang Y, Isom HC, Kester M, Staveley-O'Carroll KF (2011) Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 60(5):695-701
63. Tan KB, Ling LU, Bunte RM, Chng WJ, Chiu GN (2012) In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia. J Control Release 160(2): 290-298
64. Tang YD, Pandey A, Kolmakova A, Wang XT, Venkatraman SS, Chatterjee S, Boey FY (2009) Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus. Glycoconj J 26(6):721-732
65. Tran MA, Smith CD, Kester M, Robertson GP (2008) Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 14(11):3571-3581
66. van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA (2011) Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy insolid tumors. FASEB J 25(1):280-289
67. van Vlerken LE, Duan Z, Seiden MV, Amiji MM (2007) Modulation of intracellular eramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 67(10): 4843-4850
68. Yilmaz E, Borchert HH (2006) Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema - an in vivo study. Int J Pharm 307(2):232-238
69. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ (2010) Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol 27(7):286-298
70. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE (2008) Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 36(8): 1709-1715